Sharyn D Baker

List of Publications by Year in Descending Order

198 papers	9,557 citations	58 h-index	91 g-index
210 ext. papers	10,533 ext. citations	6.2 avg, IF	5.41 L-index

#	Paper	IF	Citations
198	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.. *Cancer Research Communications*, **2021**, 1, 79-89		1
197	High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML. *Blood*, **2021**, 138, 207-207	2.2	0
196	Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia. *Blood Advances*, **2021**, 5, 5041-5046	7.8	1
195	Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. *Basic and Clinical Pharmacology and Toxicology*, **2021**,	3.1	4
194	DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. *Clinical and Translational Science*, **2021**, 14, 137-142	4.9	6
193	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	7
192	Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1179, 122882	3.2	1
191	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. *Blood Cancer Discovery*, **2021**, 2, 586-599	7	0
190	Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. *Kidney International*, **2021**, 100, 1214-1226	9.9	2
189	Gilteritinib Inhibits Glutamine Uptake and Utilization in -ITD-Positive AML. *Molecular Cancer Therapeutics*, **2021**, 20, 2207-2217	6.1	2
188	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. *Journal of Hematology and Oncology*, **2020**, 13, 8	22.4	11
187	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. *Drug Metabolism and Disposition*, **2020**, 48, 419-425	4	15
186	TP-0903 is active in models of drug-resistant acute myeloid leukemia. *JCI Insight*, **2020**, 5,	9.9	6
185	Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2020**, 1152, 122176	3.2	6
184	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. *Pharmaceutics*, **2020**, 12,	6.4	2
183	Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. *Pharmaceutics*, **2020**, 12,	6.4	9
182	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. *Investigational New Drugs*, **2020**, 38, 340-349	4.3	13

181	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. *Leukemia*, **2020**, 34, 735-745	10.7	14
180	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 227-237	6.1	16
179	A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. *Nature Communications*, **2020**, 11, 1924	17.4	10
178	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. *Clinical Cancer Research*, **2019**, 25, 7320-7330	12.9	10
177	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. *Nature Communications*, **2019**, 10, 2189	17.4	9
176	Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice. *Clinical and Translational Science*, **2019**, 12, 400-407	4.9	7
175	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. *Clinical and Translational Science*, **2019**, 12, 641-647	4.9	5
174	Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia. *FASEB Journal*, **2019**, 33, 675.2	0.9	
173	Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. *Pharmacology Research and Perspectives*, **2019**, 7, e00534	3.1	6
172	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. *Nature Communications*, **2019**, 10, 244	17.4	63
171	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. *Journal of Clinical Investigation*, **2018**, 128, 369-380	15.9	25
170	Hypoxia Reporter Element Assay. *Bio-protocol*, **2018**, 8,	0.9	1
169	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2018**, 1090, 43-51	3.2	8
168	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. *Leukemia and Lymphoma*, **2017**, 58, 247-250	1.9	4
167	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. *Cancer Research*, **2017**, 77, 2102-2111	10.1	30
166	A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). *Pediatric Blood and Cancer*, **2017**, 64, e26414	3	46
165	Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. *ACS Omega*, **2017**, 2, 1985-2009	3.9	8
164	Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. *Cancer*, **2017**, 123, 3602-3608	6.4	6

163	E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. *Leukemia*, **2017**, 31, 502-505	10.7	8
162	Clinical significance of in vivo cytarabine-induced gene expression signature in AML. *Leukemia and Lymphoma*, **2016**, 57, 909-20	1.9	5
161	A phosphotyrosine switch regulates organic cation transporters. *Nature Communications*, **2016**, 7, 10880	17.4	74
160	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. *Clinical Pharmacology and Therapeutics*, **2016**, 99, 651-60	6.1	19
159	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. *Cancer Research*, **2016**, 76, 117-26	10.1	33
158	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. *Blood*, **2016**, 128, 3937-3937	2.2	3
157	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. *Blood*, **2016**, 128, 2838-2838	2.2	
156	Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 1039-52	3.5	30
155	Evaluation of artemisinins for the treatment of acute myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 1231-43	3.5	30
154	Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5855-5860	3.4	6
153	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. *Cancer Research*, **2015**, 75, 2729-36	10.1	46
152	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. *Cancer Cell*, **2015**, 28, 343-56	24.3	114
151	Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. *Blood*, **2015**, 126, 3695-3695	2.2	3
150	Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. *British Journal of Cancer*, **2014**, 110, 894-8	8.7	38
149	Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). *Clinical Cancer Research*, **2014**, 20, 985-94	12.9	45
148	Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 3620-3620	2.2	
147	Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. *Clinical Cancer Research*, **2013**, 19, 236-46	12.9	56
146	Alternative formulations of sorafenib for use in children. *Pediatric Blood and Cancer*, **2013**, 60, 1642-6	3	8

145	Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. *Clinical Cancer Research*, **2013**, 19, 4359-4370	12.9	34
144	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. *Clinical Cancer Research*, **2013**, 19, 1458-66	12.9	109
143	Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. *Clinical Cancer Research*, **2013**, 19, 5758-68	12.9	74
142	Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. *Clinical Cancer Research*, **2013**, 19, 3050-8	12.9	67
141	The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 242-52	36.3	474
140	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. *Blood*, **2013**, 122, 3607-15	2.2	140
139	Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. *PLoS ONE*, **2013**, 8, e79106	3.7	63
138	TAK1 is a Regulator of Sorafenib-induced Keratinocyte Toxicity. *FASEB Journal*, **2013**, 27, 657.1	0.9	
137	Genetic variations in cytarabine pathway genes as determinants of outcome in acute myeloid leukemia.. *Journal of Clinical Oncology*, **2013**, 31, 10005-10005	2.2	
136	Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS. *Blood*, **2013**, 122, 2680-2680	2.2	1
135	Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. *British Journal of Cancer*, **2012**, 107, 1100-6	8.7	50
134	OATP1B1 polymorphism as a determinant of erythromycin disposition. *Clinical Pharmacology and Therapeutics*, **2012**, 92, 642-50	6.1	21
133	Inhibition of OCTN2-mediated transport of carnitine by etoposide. *Molecular Cancer Therapeutics*, **2012**, 11, 921-9	6.1	46
132	Ontogeny and sorafenib metabolism. *Clinical Cancer Research*, **2012**, 18, 5788-95	12.9	34
131	Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. *Clinical Cancer Research*, **2012**, 18, 4433-40	12.9	70
130	Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. *Clinical Cancer Research*, **2012**, 18, 4425-32	12.9	29
129	Recommendation of dose banding of cytotoxics according to pharmacokinetic criteria.. *Journal of Clinical Oncology*, **2012**, 30, 2549-2549	2.2	
128	Pharmacokinetic Studies in Early Anticancer Drug Development **2011**, 189-214		3

127	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. *Clinical Pharmacology and Therapeutics*, **2011**, 89, 693-701	6.1	30
126	CREBBP mutations in relapsed acute lymphoblastic leukaemia. *Nature*, **2011**, 471, 235-9	50.4	468
125	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. *Investigational New Drugs*, **2011**, 29, 1057-65	4.3	8
124	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 153-62	4.4	15
123	Marginal increase of sunitinib exposure by grapefruit juice. *Cancer Chemotherapy and Pharmacology* , **2011**, 67, 695-703	3.5	36
122	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. *Leukemia Research*, **2011**, 35, 87-94	2.7	18
121	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. *Pharmacogenomics*, **2011**, 12, 327-39	2.6	21
120	Reply to J. Gligorov et al. *Journal of Clinical Oncology*, **2011**, 29, e456-e457	2.2	1
119	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. *Journal of Clinical Oncology*, **2011**, 29, 3293-300	2.2	124
118	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. *Journal of the National Cancer Institute*, **2011**, 103, 893-905	9.7	45
117	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. *Leukemia*, **2010**, 24, 1437-44	10.7	82
116	Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. *Journal of Clinical Oncology*, **2010**, 28, 4562-7	2.2	73
115	Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2010**, 878, 3033-8	3.2	43
114	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1073-1073	2.2	1
113	A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. *Clinical Cancer Research*, **2009**, 15, 6241-9	12.9	68
112	Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. *Journal of Clinical Oncology*, **2009**, 27, 4986-93	2.2	50
111	Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. *Clinical Cancer Research*, **2009**, 15, 6062-9	12.9	132
110	Pharmacokinetic considerations for new targeted therapies. *Clinical Pharmacology and Therapeutics* , **2009**, 85, 208-11	6.1	26

109	Pharmacogenetic pathway analysis of docetaxel elimination. *Clinical Pharmacology and Therapeutics*, **2009**, 85, 155-63	6.1	135
108	Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 274-8	4.7	34
107	Chemotherapy in the Pediatric Patient **2009**, 173-207		0
106	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 114-114	2.2	1
105	Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment.. *Blood*, **2009**, 114, 1734-1734	2.2	
104	Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. *Clinical Pharmacology and Therapeutics*, **2008**, 84, 704-9	6.1	45
103	Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. *Clinical Pharmacology and Therapeutics*, **2008**, 83, 477-84	6.1	44
102	Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. *Clinical Pharmacology and Therapeutics*, **2008**, 84, 111-8	6.1	39
101	Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. *Journal of Clinical Oncology*, **2008**, 26, 5504-10	2.2	94
100	Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. *Clinical Cancer Research*, **2008**, 14, 2102-10	12.9	20
99	Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. *British Journal of Cancer*, **2008**, 98, 1630-2	8.7	21
98	Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. *Journal of Clinical Oncology*, **2008**, 26, 2959-65	2.2	27
97	Interaction of imatinib with human organic ion carriers. *Clinical Cancer Research*, **2008**, 14, 3141-8	12.9	176
96	Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. *Annals of Oncology*, **2008**, 19, 374-9	10.3	3
95	Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. *Journal of Clinical Oncology*, **2008**, 26, 4172-9	2.2	58
94	Stability of sunitinib in oral suspension. *Annals of Pharmacotherapy*, **2008**, 42, 962-6	2.9	10
93	Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. *Cancer Chemotherapy and Pharmacology*, **2008**, 61, 423-33	3.5	32
92	Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2008**, 874, 84-8	3.2	52

91	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. *Molecular Cancer Therapeutics*, **2008**, 7, 1110-20	6.1	40
90	Gene Expression Profiling of Acute Myeloid Leukemia Shows Therapeutically Meaningful Patterns of Association with Ara-CTP Pharmacokinetics and Pharmacodynamics. *Blood*, **2008**, 112, 215-215	2.2	
89	Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.. *Blood*, **2008**, 112, 1630-1630	2.2	
88	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2007**, 846, 1-7	3.2	43
87	Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. *Investigational New Drugs*, **2007**, 25, 237-45	4.3	5
86	A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*, **2007**, 43, 784-7	3.5	10
85	Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. *Clinical Cancer Research*, **2007**, 13, 7394-400	12.9	88
84	Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. *Cancer Biology and Therapy*, **2007**, 6, 891-7	4.6	14
83	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. *Cancer Biology and Therapy*, **2007**, 6, 432-8	4.6	159
82	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. *Clinical Cancer Research*, **2007**, 13, 3731-7	12.9	237
81	Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. *Journal of Clinical Oncology*, **2007**, 25, 4707-13	2.2	123
80	Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. *Clinical Cancer Research*, **2007**, 13, 2488-95	12.9	88
79	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. *European Journal of Cancer*, **2007**, 43, 78-86	7.5	3
78	Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).. *Blood*, **2007**, 110, 4202-4202	2.2	
77	Pharmacokinetics and toxicity of weekly docetaxel in older patients. *Clinical Cancer Research*, **2006**, 12, 6100-5	12.9	65
76	Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. *Journal of Clinical Oncology*, **2006**, 24, 552-62	2.2	86
75	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. *Journal of the National Cancer Institute*, **2006**, 98, 1714-23	9.7	93
74	Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. *Clinical Cancer Research*, **2006**, 12, 536-42	12.9	30

73	Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. *Clinical Cancer Research*, **2006**, 12, 1270-5	12.9	46
72	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. *Journal of the National Cancer Institute*, **2006**, 98, 1739-42	9.7	218
71	Ductal access for prevention and therapy of mammary tumors. *Cancer Research*, **2006**, 66, 638-45	10.1	64
70	Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. *Clinical Cancer Research*, **2006**, 12, 2158-65	12.9	11
69	Clinical pharmacokinetics of docetaxel : recent developments. *Clinical Pharmacokinetics*, **2006**, 45, 235-52	6.2	125
68	Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2006**, 29, 395-8	2.7	19
67	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. *Clinical Pharmacology and Therapeutics*, **2006**, 80, 192-201	6.1	105
66	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2006**, 42, 253-60	3.5	6
65	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. *Investigational New Drugs*, **2006**, 24, 291-7	4.3	60
64	A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. *Investigational New Drugs*, **2006**, 24, 499-508	4.3	16
63	A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. *Journal of Pharmaceutical and Biomedical Analysis*, **2005**, 37, 751-6	3.5	4
62	Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2005**, 819, 73-80	3.2	52
61	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2005**, 828, 41-54	3.2	1
60	Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. *Analytical Biochemistry*, **2005**, 337, 143-8	3.1	10
59	Relationship of systemic exposure to unbound docetaxel and neutropenia. *Clinical Pharmacology and Therapeutics*, **2005**, 77, 43-53	6.1	68
58	Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. *Neuro-Oncology*, **2005**, 7, 177-82	1	70
57	Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. *Clinical Cancer Research*, **2005**, 11, 7398-404	12.9	60
56	In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. *Clinical Cancer Research*, **2005**, 11, 8503-11	12.9	9

55	Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. *Journal of Clinical Oncology*, **2005**, 23, 1070-7	2.2	92
54	Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. *Journal of Clinical Oncology*, **2005**, 23, 3906-11	2.2	88
53	Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?. *Journal of Clinical Oncology*, **2005**, 23, 7765-7	2.2	29
52	Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. *Clinical Cancer Research*, **2005**, 11, 7800-6	12.9	102
51	Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.. *Blood*, **2005**, 106, 2792-2792	2.2	1
50	A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. *Clinical Cancer Research*, **2005**, 11, 664-71	12.9	48
49	Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. *Clinical Cancer Research*, **2004**, 10, 1976-83	12.9	98
48	Factors affecting cytochrome P-450 3A activity in cancer patients. *Clinical Cancer Research*, **2004**, 10, 8341-50	12.9	107
47	Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. *Pharmacotherapy*, **2004**, 24, 16-25	5.8	22
46	A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. *Biomedical Chromatography*, **2004**, 18, 282-7	1.7	2
45	Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2004**, 813, 81-8	3.2	33
44	Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 448-54	6.1	94
43	Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. *Analytical Biochemistry*, **2004**, 324, 276-84	3.1	67
42	An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. *Cancer Research*, **2004**, 64, 9139-43	10.1	224
41	Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry. *Steroids*, **2004**, 69, 721-6	2.8	46
40	Limited cerebrospinal fluid penetration of docetaxel. *Anti-Cancer Drugs*, **2004**, 15, 715-8	2.4	14
39	Determination of fraction unbound docetaxel using microequilibrium dialysis. *Analytical Biochemistry*, **2004**, 331, 192-194	3.1	15
38	Pharmacokinetic Modeling **2004**, 129-137		

37	Determination of fraction unbound docetaxel using microequilibrium dialysis. *Analytical Biochemistry*, **2004**, 331, 192-4	3.1	6
36	Distribution of paclitaxel in plasma and cerebrospinal fluid. *Anti-Cancer Drugs*, **2003**, 14, 365-8	2.4	8
35	Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. *Clinical Pharmacology and Therapeutics*, **2003**, 74, 509-10	6.1	10
34	Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. *Clinical Pharmacology and Therapeutics*, **2003**, 74, 364-71	6.1	81
33	A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2003**, 33, 725-33	3.5	3
32	Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2003**, 793, 413-20	3.2	55
31	Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. *Clinical Cancer Research*, **2003**, 9, 151-9	12.9	39
30	Irinotecan pathway genotype analysis to predict pharmacokinetics. *Clinical Cancer Research*, **2003**, 9, 3246-53	12.9	164
29	Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. *Clinical Cancer Research*, **2003**, 9, 3589-97	12.9	54
28	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. *Journal of Clinical Oncology*, **2002**, 20, 656-64	2.2	69
27	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. *Journal of Clinical Oncology*, **2002**, 20, 96-109	2.2	30
26	Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 773, 183-90	3.2	32
25	Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. *Journal of Clinical Oncology*, **2002**, 20, 2567-74	2.2	20
24	Troxacitabine in patients with refractory leukemia. *Journal of Clinical Oncology*, **2002**, 20, 3356; author reply 3356-7	2.2	1
23	Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. *Journal of the National Cancer Institute*, **2002**, 94, 1883-8	9.7	211
22	Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. *Molecular Cancer Therapeutics*, **2002**, 1, 545-52	6.1	170
21	Tumor targeting by conjugation of DHA to paclitaxel. *Journal of Controlled Release*, **2001**, 74, 233-6	11.7	78
20	Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. *Journal of Clinical Oncology*, **2001**, 19, 762-71	2.2	91

19	Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2000**, 23, 609-13	2.7	2
18	Pharmacology of fluorinated pyrimidines: eniluracil. *Investigational New Drugs*, **2000**, 18, 373-81	4.3	18
17	Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. *Journal of Clinical Oncology*, **2000**, 18, 915-26	2.2	62
16	Population pharmacokinetic model for topotecan derived from phase I clinical trials. *Journal of Clinical Oncology*, **2000**, 18, 2459-67	2.2	50
15	Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. *Journal of Clinical Oncology*, **2000**, 18, 4086-97	2.2	44
14	Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. *Journal of Clinical Oncology*, **1999**, 17, 1095-104	2.2	57
13	Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. *Journal of Clinical Oncology*, **1999**, 17, 2604-13	2.2	101
12	A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. *Cancer Chemotherapy and Pharmacology*, **1999**, 44, 372-80	3.5	147
11	Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy. *Experimental Cell Research*, **1998**, 241, 332-9	4.2	11
10	A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. *Annals of Oncology*, **1998**, 9, 101-4	10.3	21
9	High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. *Annals of Oncology*, **1998**, 9, 173-80	10.3	7
8	Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. *Journal of Clinical Oncology*, **1998**, 16, 2770-9	2.2	31
7	Pharmacology of Cancer Chemotherapy in the Older Person. *Clinics in Geriatric Medicine*, **1997**, 13, 169-183	3.3	103
6	Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. *Cancer Chemotherapy and Pharmacology*, **1996**, 37, 195-202	3.5	105
5	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. *Journal of Clinical Oncology*, **1996**, 14, 1504-11	2.2	57
4	Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. *Journal of Clinical Oncology*, **1996**, 14, 3074-84	2.2	126
3	Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. *Journal of Clinical Oncology*, **1996**, 14, 3085-96	2.2	117
2	Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. *Cytometry*, **1995**, 19, 134-45		35

1	Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. *Journal of Clinical Oncology*, **1994**, 12, 1946-54	2.2	77